Presentation of Results on Nymox Pharmaceutical NX-1207 BPH Drug in New Orleans October 28 at Meeting of American Urological Association

Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that new clinical trial data concerning the safety and efficacy of the Company's NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the North Eastern Section of the American Urological Association Meeting in New Orleans, LA October 28, 2011. The presentation is authored by Neal Shore MD FACS, of Myrtle Beach, SC, Sheldon Freedman MD FACS, of Las Vegas, NV, Barton Wachs, MD FACS, of Long Beach, CA and Barrett Cowan, MD FACS, of Denver, CO.